查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1916705

全球人工智慧診斷市場：未來預測（至2032年）－按組件、類型、技術、應用、最終用戶和地區進行分析

AI Diagnostics Market Forecasts to 2032 - Global Analysis By Component (Software, Hardware and Services), Type, Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的一項研究，預計到 2025 年，全球人工智慧診斷市場價值將達到 74.8 億美元，到 2032 年將達到 1028.7 億美元，在預測期內的複合年成長率為 45.4%。

人工智慧診斷是指應用人工智慧技術，例如機器學習、深度學習和數據分析，來輔助檢測、分析和解讀疾病。人工智慧系統能夠處理大量的患者數據、醫學影像和臨床記錄，以高精度和高速度識別疾病模式和異常情況，從而輔助臨床醫生進行決策。這些工具有助於疾病的早期發現，提高診斷準確率，減少人為錯誤，並最佳化治療方案。人工智慧診斷涵蓋放射學、病理學、心臟病學和基因組學等多個領域，正在將傳統的醫療實踐轉變為更有效率、數據驅動且更具預測性的方法。

將巨量資料整合到醫療保健領域

巨量資料在醫療保健領域的應用是推動人工智慧診斷市場發展的主要因素。透過利用源自電子健康記錄、醫學影像和基因組圖譜的大量資料集，人工智慧系統能夠提供精準的洞察、預測分析和個人化的治療建議。這種能力提高了臨床決策的準確性，提升了營運效率，並加快了疾病檢測速度。人工智慧與巨量資料的融合使醫療服務提供者能夠識別以往未曾發現的模式和趨勢，從而推動了全球範圍內人工智慧診斷技術的普及和市場成長。

高昂的實施成本

高昂的實施成本仍然是人工智慧診斷市場的主要阻礙因素。部署人工智慧解決方案需要對硬體、軟體和專業人員進行大量投資，並且還需要持續的系統維護和更新。小規模的醫療機構和新興市場可能面臨實施方面的財務障礙。此外，與現有醫療基礎設施整合以及遵守資料安全標準也會增加成本。這些財務和營運方面的挑戰可能會減緩市場滲透速度，並限制其廣泛應用，尤其是在資源匱乏的地區。

政府主導的政策和投資

政府的各項措施和投資為市場帶來了巨大的機會。扶持性政策、資助計畫和夥伴關係將鼓勵人工智慧醫療解決方案的研究、開發和應用。鼓勵醫院採用數位化醫療技術和整合人工智慧的獎勵將加速創新並擴大醫療服務的可近性。這些措施將有助於克服基礎設施和成本方面的挑戰，從而促進市場成長。加強公私合營和政府支持的先導計畫將增強信任，並為人工智慧診斷技術的廣泛應用鋪平道路，使其惠及從新興經濟體到先進醫療體系的各個層面。

監理不確定性

監管的不確定性對市場構成重大威脅。核准流程、合規標準和資料隱私法規的不斷變化可能會延緩人工智慧技術的部署和商業化。不同地區醫療保健領域人工智慧法律體制的差異，也使全球推廣應用變得更加複雜。責任認定和演算法透明度方面的模糊性可能會抑制投資並減緩創新。企業必須在複雜的法規環境運作，以確保安全性、有效性和合乎倫理的使用，而監管的不確定性則持續為市場穩定帶來挑戰。

新冠疫情的感染疾病：

新冠疫情加速了人工智慧診斷技術的應用，並凸顯了其在應對大規模醫療挑戰方面的潛力。人工智慧能夠快速分析醫學影像和患者數據，並預測感染趨勢。遠距離診斷和遠端保健解決方案迅速普及，有助於減輕醫療機構的壓力，提高臨床效率。然而，疫情也擾亂了供應鏈，延緩了部分部署，並暫時轉移了投資方向。整體而言，新冠疫情既是疫情應對和未來醫療韌性發展的催化劑，也是挑戰。

預計在預測期內，機器學習領域將佔據最大的市場佔有率。

預計在預測期內，機器學習領域將佔據最大的市場佔有率，因為系統能夠從歷史患者數據、醫學影像和臨床結果中學習，從而不斷提高診斷準確率。這項功能有助於疾病的早期檢測、預測建模和個人化治療方案的發展。其在包括放射學和病理學在內的多個專科領域的適用性，使其成為醫療服務提供者極具價值的技術。先進演算法的日益普及及其與巨量資料分析的融合，將確保機器學習解決方案的持續成長和市場主導地位。

預計在預測期內，腫瘤治療領域將達到最高的複合年成長率。

預計在預測期內，腫瘤學領域將實現最高成長率，因為人工智慧技術透過先進的成像、基因組分析和預測建模，促進了癌症的早期檢測和治療方案的發展。癌症發生率的上升以及對精準化和個人化治療方法的需求，正在推動腫瘤診斷技術的應用。人工智慧提高了識別惡性腫瘤和預測疾病進展的準確性，從而輔助臨床醫生進行決策。對人工智慧腫瘤解決方案的持續創新和投資，正在推動該領域的顯著成長。

佔比最大的地區：

由於數位化加快以及人們對人工智慧解決方案的認知度不斷提高，預計亞太地區將在預測期內佔據最大的市場佔有率。醫院基礎設施的擴建、慢性病盛行率的上升以及政府鼓勵採用數位醫療的舉措將進一步推動市場成長。此外，技術提供者與醫療機構之間的合作正使人工智慧診斷更加普及和整合。亞太地區人口密度高，加上醫療保健支出不斷成長，將使其成為全球市場擴張的主要驅動力。

年複合成長率最高的地區：

預計北美地區在預測期內將實現最高的複合年成長率，這得益於其強大的技術基礎設施和對人工智慧驅動解決方案的早期應用。政府的支持性政策、大量的私人投資以及主要人工智慧醫療公司的入駐正在加速創新。先進的研究舉措、大規模臨床數據的獲取以及患者的高度認知進一步增強了市場動態。這些因素的綜合作用將使北美實現顯著成長，並保持其在全球人工智慧診斷應用領域的主導地位。

免費客製化服務：

訂閱本報告的用戶可從以下免費自訂選項中選擇一項：

  • 公司簡介
    • 對最多三家其他公司進行全面分析
    • 對主要企業進行SWOT分析（最多3家公司）
  • 區域分類
    • 根據客戶興趣對主要國家進行市場估算、預測和複合年成長率分析（註：基於可行性檢查）
  • 競爭標竿分析
    • 基於產品系列、地域覆蓋和策略聯盟對主要企業進行基準分析

目錄

第1章執行摘要

第2章 引言

  • 概述
  • 相關利益者
  • 分析範圍
  • 分析方法
  • 分析材料

第3章 市場趨勢分析

  • 促進要素
  • 抑制因素
  • 機會
  • 威脅
  • 技術分析
  • 應用分析
  • 終端用戶分析
  • 新興市場
  • 新冠疫情的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代產品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

第5章 全球人工智慧診斷市場（按組件分類）

  • 軟體
  • 硬體
  • 服務

第6章 全球人工智慧診斷市場（按類型分類）

  • 體外診斷
  • 影像診斷
  • 其他類型

第7章 全球人工智慧診斷市場（按技術分類）

  • 機器學習
  • 深度學習
  • 自然語言處理
  • 電腦視覺

第8章 全球人工智慧診斷市場（按應用分類）

  • 放射學和診斷影像
  • 病理
  • 心臟病
  • 瘤
  • 神經系統疾病
  • 其他用途

第9章 全球人工智慧診斷市場（按最終用戶分類）

  • 醫院
  • 診斷檢查室
  • 診斷影像中心
  • 其他最終用戶

第10章 全球人工智慧診斷市場（按地區分類）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 亞太其他地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美洲
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第11章：主要趨勢

  • 合約、商業夥伴關係和合資企業
  • 企業合併（M&A）
  • 新產品上市
  • 業務拓展
  • 其他關鍵策略

第12章：公司簡介

  • GE HealthCare
  • Digital Diagnostics Inc.
  • Koninklijke Philips NV
  • Tempus AI, Inc.
  • Microsoft Corporation
  • Qure.ai
  • Google LLC
  • Zebra Medical Vision
  • NVIDIA Corporation
  • Ibex Medical Analytics
  • IBM Corporation
  • Lunit Inc.
  • Aidoc Medical Ltd
  • Siemens Healthineers AG
  • PathAI, Inc.
Product Code: SMRC33278

According to Stratistics MRC, the Global AI Diagnostics Market is accounted for $7.48 billion in 2025 and is expected to reach $102.87 billion by 2032 growing at a CAGR of 45.4% during the forecast period. AI Diagnostics refers to the application of artificial intelligence technologies, including machine learning, deep learning, and data analytics, to assist in the detection, analysis, and interpretation of medical conditions. By processing vast amounts of patient data, medical images, and clinical records, AI systems can identify patterns and anomalies with high accuracy and speed, supporting clinicians in decision-making. These tools enhance early disease detection, improve diagnostic precision, reduce human error, and optimize treatment planning. AI diagnostics spans multiple areas, including radiology, pathology, cardiology, and genomics, transforming traditional healthcare practices into more efficient, data-driven, and predictive approaches.

Market Dynamics:

Driver:

Integration of Big Data in Healthcare

The integration of big data in healthcare is a primary driver for the AI diagnostics market. Leveraging massive datasets from electronic health records, medical imaging, and genomic profiles, AI systems can deliver precise insights, predictive analytics, and personalized treatment recommendations. This capability improves clinical decision-making, enhances operational efficiency, and accelerates disease detection. The convergence of AI and big data enables healthcare providers to identify patterns and trends that were previously inaccessible, driving adoption and market growth globally.

Restraint:

High Implementation Costs

High implementation costs remain a significant restraint for the AI diagnostics market. Deploying AI solutions requires substantial investment in hardware, software, and skilled personnel, along with continuous system maintenance and updates. Smaller healthcare facilities and emerging markets may face financial barriers to adoption. Additionally, integration with existing medical infrastructure and compliance with data security standards adds to the expense. These financial and operational challenges can slow market penetration, particularly in resource-limited regions, restricting widespread adoption.

Opportunity:

Government Initiatives & Investments

Government initiatives and investments present a major opportunity for the market. Supportive policies, funding programs, and partnerships encourage research, development, and deployment of AI-powered healthcare solutions. Incentives for digital health adoption and AI integration in hospitals accelerate innovation and expand accessibility. Such efforts help overcome infrastructure and cost challenges, fostering market growth. Increased public-private collaborations and government-backed pilot projects promote trust, and open avenues for AI diagnostics across emerging economies and developed healthcare systems.

Threat:

Regulatory Uncertainty

Regulatory uncertainty poses a notable threat to the market. The evolving landscape of approvals, compliance standards, and data privacy regulations can delay deployment and commercialization of AI technologies. Different regions maintain varying legal frameworks for AI in healthcare, complicating global adoption. Ambiguities around liability and algorithm transparency may deter investment and slow innovation. Companies must navigate complex regulatory environments to ensure safety, efficacy, and ethical use, making regulatory unpredictability a persistent challenge impacting market stability.

Covid-19 Impact:

The Covid-19 pandemic accelerated the adoption of AI diagnostics, highlighting its potential in managing large-scale healthcare challenges. AI enabled rapid analysis of medical images, patient data, and predictive modeling for outbreak trends. Remote diagnostics and telehealth solutions gained prominence, reducing strain on healthcare facilities and enhancing clinical efficiency. However, the pandemic also disrupted supply chains, slowed certain implementations, and temporarily diverted investments. Overall, Covid-19 acted as both a catalyst and a challenge, in pandemic response and future healthcare resilience.

The machine learning segment is expected to be the largest during the forecast period

The machine learning segment is expected to account for the largest market share during the forecast period as it enable systems to learn from historical patient data, medical images, and clinical outcomes, continuously improving diagnostic accuracy. This capability supports early disease detection, predictive modeling, and personalized treatment planning. Its adaptability across multiple specialties, including radiology and pathology, makes it highly valuable for healthcare providers. Increasing adoption of advanced algorithms and integration with big data analytics ensures sustained growth and a leading market share for machine learning solutions.

The oncology segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the oncology segment is predicted to witness the highest growth rate, as AI technologies facilitate early cancer detection and treatment planning through advanced imaging, genomic analysis, and predictive modeling. The rising prevalence of cancer, coupled with demand for precise and personalized therapies, drives adoption in oncology diagnostics. AI enhances accuracy in identifying malignancies and predicting disease progression, supporting clinicians in decision-making. Continuous innovations and investments in AI-powered oncology solutions position this segment for significant growth.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share, due to rapid digitization, and growing awareness of AI solutions. Expanding hospital infrastructure, rising chronic disease prevalence and government initiatives promoting digital health adoption further drives market growth. Additionally, collaboration between technology providers and healthcare institutions enhances accessibility and integration of AI diagnostics. A combination of high population density and increasing healthcare expenditure positions Asia Pacific as a key contributor to global market expansion.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, owing to Strong technological infrastructure and early adoption of AI-driven solutions contribute to rapid growth. Supportive government policies, substantial private investments, and the presence of major AI healthcare companies accelerate innovation. Advanced research initiatives, access to large-scale clinical data, and high patient awareness further strengthen market dynamics. These factors collectively enable North America to achieve significant growth and maintain a leadership position in AI diagnostics adoption globally.

Key players in the market

Some of the key players in AI Diagnostics Market include GE HealthCare, Digital Diagnostics Inc., Koninklijke Philips N.V., Tempus AI, Inc., Microsoft Corporation, Qure.ai, Google LLC, Zebra Medical Vision, NVIDIA Corporation, Ibex Medical Analytics, IBM Corporation, Lunit Inc., Aidoc Medical Ltd, Siemens Healthineers AG, and PathAI, Inc.,

Key Developments:

In November 2025, Siemens Healthineers introduced Syngo Carbon 2.0, an upgraded enterprise imaging platform. The launch integrates multimodal imaging data, AI-powered workflow automation, and cloud-based collaboration, designed to streamline radiology operations and improve diagnostic accuracy across global healthcare systems.

In October 2025, Siemens Healthineers expanded its collaboration with Varian and multiple oncology centers to accelerate precision therapy solutions. The joint venture integrates imaging, radiation therapy, and AI-driven planning tools, aiming to improve cancer treatment outcomes and strengthen Siemens' leadership in oncology care.

Components Covered:

  • Software
  • Hardware
  • Services

Types Covered:

  • In Vitro Diagnostics
  • Diagnostic Imaging
  • Other Types

Technologies Covered:

  • Machine Learning
  • Deep Learning
  • Natural Language Processing
  • Computer Vision

Applications Covered:

  • Radiology & Imaging
  • Pathology
  • Cardiology
  • Oncology
  • Neurology
  • Other Applications

End Users Covered:

  • Hospitals
  • Diagnostic Laboratories
  • Diagnostic Imaging Centers
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global AI Diagnostics Market, By Component

  • 5.1 Introduction
  • 5.2 Software
  • 5.3 Hardware
  • 5.4 Services

6 Global AI Diagnostics Market, By Type

  • 6.1 Introduction
  • 6.2 In Vitro Diagnostics
  • 6.3 Diagnostic Imaging
  • 6.4 Other Types

7 Global AI Diagnostics Market, By Technology

  • 7.1 Introduction
  • 7.2 Machine Learning
  • 7.3 Deep Learning
  • 7.4 Natural Language Processing
  • 7.5 Computer Vision

8 Global AI Diagnostics Market, By Application

  • 8.1 Introduction
  • 8.2 Radiology & Imaging
  • 8.3 Pathology
  • 8.4 Cardiology
  • 8.5 Oncology
  • 8.6 Neurology
  • 8.7 Other Applications

9 Global AI Diagnostics Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals
  • 9.3 Diagnostic Laboratories
  • 9.4 Diagnostic Imaging Centers
  • 9.5 Other End Users

10 Global AI Diagnostics Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 GE HealthCare
  • 12.2 Digital Diagnostics Inc.
  • 12.3 Koninklijke Philips N.V.
  • 12.4 Tempus AI, Inc.
  • 12.5 Microsoft Corporation
  • 12.6 Qure.ai
  • 12.7 Google LLC
  • 12.8 Zebra Medical Vision
  • 12.9 NVIDIA Corporation
  • 12.10 Ibex Medical Analytics
  • 12.11 IBM Corporation
  • 12.12 Lunit Inc.
  • 12.13 Aidoc Medical Ltd
  • 12.14 Siemens Healthineers AG
  • 12.15 PathAI, Inc.

List of Tables

  • Table 1 Global AI Diagnostics Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global AI Diagnostics Market Outlook, By Component (2024-2032) ($MN)
  • Table 3 Global AI Diagnostics Market Outlook, By Software (2024-2032) ($MN)
  • Table 4 Global AI Diagnostics Market Outlook, By Hardware (2024-2032) ($MN)
  • Table 5 Global AI Diagnostics Market Outlook, By Services (2024-2032) ($MN)
  • Table 6 Global AI Diagnostics Market Outlook, By Type (2024-2032) ($MN)
  • Table 7 Global AI Diagnostics Market Outlook, By In Vitro Diagnostics (2024-2032) ($MN)
  • Table 8 Global AI Diagnostics Market Outlook, By Diagnostic Imaging (2024-2032) ($MN)
  • Table 9 Global AI Diagnostics Market Outlook, By Other Types (2024-2032) ($MN)
  • Table 10 Global AI Diagnostics Market Outlook, By Technology (2024-2032) ($MN)
  • Table 11 Global AI Diagnostics Market Outlook, By Machine Learning (2024-2032) ($MN)
  • Table 12 Global AI Diagnostics Market Outlook, By Deep Learning (2024-2032) ($MN)
  • Table 13 Global AI Diagnostics Market Outlook, By Natural Language Processing (2024-2032) ($MN)
  • Table 14 Global AI Diagnostics Market Outlook, By Computer Vision (2024-2032) ($MN)
  • Table 15 Global AI Diagnostics Market Outlook, By Application (2024-2032) ($MN)
  • Table 16 Global AI Diagnostics Market Outlook, By Radiology & Imaging (2024-2032) ($MN)
  • Table 17 Global AI Diagnostics Market Outlook, By Pathology (2024-2032) ($MN)
  • Table 18 Global AI Diagnostics Market Outlook, By Cardiology (2024-2032) ($MN)
  • Table 19 Global AI Diagnostics Market Outlook, By Oncology (2024-2032) ($MN)
  • Table 20 Global AI Diagnostics Market Outlook, By Neurology (2024-2032) ($MN)
  • Table 21 Global AI Diagnostics Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 22 Global AI Diagnostics Market Outlook, By End User (2024-2032) ($MN)
  • Table 23 Global AI Diagnostics Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 24 Global AI Diagnostics Market Outlook, By Diagnostic Laboratories (2024-2032) ($MN)
  • Table 25 Global AI Diagnostics Market Outlook, By Diagnostic Imaging Centers (2024-2032) ($MN)
  • Table 26 Global AI Diagnostics Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.